Healthways (HWAY) Tops Q4 EPS by 4c, Offers FY16 Guidance

Healthways (NASDAQ: HWAY) reported Q4 EPS of ($0.04), $0.04 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $186.3 million versus the consensus estimate of $180.49 million.

2016 Financial Guidance

Healthways today has established its financial guidance for 2016, as follows:

• Adjusted for an aggregate year over year revenue reduction of $39 million from the HMSA contract amendment and the sale of Navvis, guidance for 2016 revenue is for a percentage growth rate in the low to middle single digits range.
• Beginning in 2016, the Company will exclude non-cash share-based compensation from adjusted EBITDA. Guidance for 2016 adjusted EBITDA, which also excludes restructuring charges, is in a range of $85 million to $90 million, compared with adjusted EBITDA for 2015 of $80 million, which excludes non-cash share-based compensation, restructuring charges, joint venture investment impairment and related loss on the remaining investment commitment, CEO transition-related expenses and gain on the sale of Navvis.
• The Company expects to use its free cash flow to reduce its debt by at least $30 million at December 31, 2016, compared with December 31, 2015.

For earnings history and earnings-related data on Healthways (HWAY) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Eikon Therapeutics, Inc. (EIKN) Misses Q2 EPS by 163c
• KinderCare Learning Companies, Inc. (KLC) Misses Q2 EPS by 2c; Offers Guidance